Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/30/12
End: 05/31/16
Due: 05/31/17
Phase: N/A
Priority: Normal
Start: 10/31/12
End: 10/31/17
Due: 10/31/18
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases | NCT01763385 | Wu Jieping Medical Foundation | user2@example.com | None | 2012-11-30 | 2016-05-31 | 2017-05-31 | - | - | 2025-07-14 |
| The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment | NCT01796288 | Wu Jieping Medical Foundation | user2@example.com | None | 2012-10-31 | 2017-10-31 | 2018-10-31 | - | - | 2025-07-14 |